Substituted benzocyloheptenes as potent and selective αv integrin antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 12, Issue 22, 2002, Pages 3291-3296

  Perron Sierra, Françoise ^a   Saint Dizier, Dominique ^a   Bertrand, Marc ^b   Genton, Annie ^a   Tucker, Gordon C ^a   Casara, Patrick ^a  

^a INSTITUT DE RECHERCHES SERVIER   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; ALPHA5 INTEGRIN; BETA3 INTEGRIN; BETA5 INTEGRIN; CILENGITIDE; FUSED ALICYCLIC AROMATIC COMPOUND; INTEGRIN; UNCLASSIFIED DRUG; ALPHAVBETA5 INTEGRIN; ARGINYL-GLYCYL-ASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; CD51 ANTIGEN; FIBRINOGEN RECEPTOR; OLIGOPEPTIDE; VITRONECTIN RECEPTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; IC 50; NONHUMAN; RAT; ANIMAL; BIOAVAILABILITY; CELL ADHESION; CELL CULTURE; CELL MEMBRANE PERMEABILITY; CONFORMATION; DRUG EFFECT; LIVER MICROSOME; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; BENZOCYCLOHEPTENES; BIOLOGICAL AVAILABILITY; CELL ADHESION; CELL MEMBRANE PERMEABILITY; HUMANS; INHIBITORY CONCENTRATION 50; INTEGRIN ALPHAV; INTEGRIN ALPHAVBETA3; INTEGRINS; MICROSOMES, LIVER; MOLECULAR CONFORMATION; OLIGOPEPTIDES; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RATS; RECEPTORS, VITRONECTIN; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0037131739     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)00696-0     Document Type: Article

References (41)

1. (a) Pytela R., Pierschbacher M.D., Ruoslahti E. Proc. Natl. Acad. Sci. U.S.A. 82:1985;5766 (b) Papadopoulos G.K., Ouzounis C., Eliopoulos E. Int. J. Biol. Macromol. 22:1998;51.
2. (a) Pytela R., Pierschbacher M.D., Ruoslahti E. Proc. Natl. Acad. Sci. U.S.A. 82:1985;5766 (b) Papadopoulos G.K., Ouzounis C., Eliopoulos E. Int. J. Biol. Macromol. 22:1998;51.
3. Storgard C.M., Stupack D.G., Jonczyk A., Goodman S.L., Fox R.I., Cheresh D.A. J. Clin. Invest. 103:1999;47.
4. (a) Hood J.D., Cheresh D.A. Nat. Rev. 21:2002;91
5. (b) Tucker G.C. Curr. Opin. Pharm. 2:2002;394
6. (c) Varner J.A., Cheresh D.A. Curr. Opin. Cell Biol. 8:1996;724
7. (d) Brooks P.C., Montgomery A.M.P., Rosenfeld M., Reisfeld R.A., Hu T., Klier G., Cheresh D.A. Cell. 79:1994;1157
8. (a) Hood J.D., Cheresh D.A. Nat. Rev. 21:2002;91 (b) Tucker G.C. Curr. Opin. Pharm. 2:2002;394 (c) Varner J.A., Cheresh D.A. Curr. Opin. Cell Biol. 8:1996;724 (d) Brooks P.C., Montgomery A.M.P., Rosenfeld M., Reisfeld R.A., Hu T., Klier G., Cheresh D.A. Cell. 79:1994;1157 (e) Mizejewski G.J. Proc. Soc. Exp. Biol. Med. 222:1999;124.
9. (a) Kerr J.S., Slee A.M., Mousa S.A. Exp. Opin. Invest. Drugs. 9:2000;1271
10. (a) Kerr J.S., Slee A.M., Mousa S.A. Exp. Opin. Invest. Drugs. 9:2000;1271 (b) Hartman G.D., Duggan M.E. Exp. Opin. Invest. Drugs. 9:2000;1281.
11. Drugs Future 2000, 25, 674.
12. Badger A.M., Blake S., Kapadia R., Sarkar S., Levin J., Swift B.A., Hoffman S.J., Stroup G.B., Miller W.H., Gowen M., Lark M.W. Arthritis Rheum. 44:2001;128.
13. Samanen J., Jonak Z., Rieman D., Yue T.L. Curr. Pharm. Des. 3:1997;545. and references cited.
14. (a) Goodman S.L., Hölzemann G., Sulyok G.A., Kessler H. J. Med. Chem. 45:2002;1045 (b) Hölzemann G. Idrugs. 4:2001;72.
15. (a) Xiong J.P., Stehle T., Diefenbach B., Zhang R., Dunker R., Scott D.L., Joachimiak A., Goodman S.L., Arnaout M.A. Science. 294:2001;339 (b) Xiong J.-P., Stehle T., Zhang R., Joachimiak A., Frech M., Goodman S.L., Arnaout M.A. Science. 296:2002;151.
16. Dechantsreiter M.A., Planker E., Mathä B., Lohof E., Hölzemann G., Jonczyk A., Goodman S.L., Kessler H. J. Med. Chem. 42:1999;3033.
17. Ewing G.D., Paquette L.A. J. Org. Chem. 40:1975;2965.
18. (a) Kita Y., Segawa J., Haruta J.-I., Yasuda H., Tamura Y. J. Chem. Soc., Perkin Trans. 1. 1982;1099 (b) Otera J., Fujita Y., Fukuzumi S., Hirai K.-I., Gu J.-H., Nakai T. Tetrahedron Lett. 36:1995;95.
19. Burford C., Cooke F., Ehlinger E., Magnus P. J. Am. Chem. Soc. 99:1977;4536.
20. Abdel-Magid A.F., Carson K.G., Harris B.D., Maryanoff C.A., Shah R.D. J. Org. Chem. 61:1996;3849.
21. Waddell T.G., Rambalakos T., Christie K.R. J. Org. Chem. 55:1990;4765.
22. Misun M., Pfaltz A. Helv. Chim. Acta. 79:1996;961.
23. Abbenante G., Prager R.H. Aust. J. Chem. 45:1992;1791.
24. (a) Miller W.H., Keenan R.M., Willette R.N., Lark M.W. Drug Discov. Today. 5:2000;397 (b) Keenan R.M., Miller W.H., Barton L.S., Bondinell W.E., Cousins R.D., Eppley D.F., Hwang S.-H., Kwon C., Lago M.A., Nguyen T.T., Smith B.R., Uzinskas I.N., Yuan C.C.K. Bioorg. Med. Chem. Lett. 9:1999;1801.
25. Tortorella V., Bettoni G. Gazz. Chim. Ital. 97:1966;85.
26. Davidsen S.K., May P.D., Summers J.B. J. Org. Chem. 56:1991;5482.
27. Arnould J.C., Landier F., Pasquet M.J. Tetrahedron Lett. 33:1992;7133.
28. Meissner R.S., Perkins J.J., Duong L.T., Hartman G.D., Hoffman W.F., Huff J.R., Ihle N.C., Leu C.-T., Nagy R.M., Neylor-Olsen A., Rodan G.A., Rodan S.B., Whitman D.B., Wesolowski G.A., Duggan M.E. Bioorg. Med. Chem. Lett. 12:2002;25.
29. Turner J.A. J. Org. Chem. 48:1983;3401.
30. Hawes E.M., Wibberley D.G. J. Chem. Soc. Org. 3:1966;315.
31. Szemes F., Rybar A., Solcaniova E. Collect. Czech. Chem. Commun. 56:1991;2986.
32. Fujita M., Egawa H., Chiba K., Matsumoto J. J. Heterocycl. Chem. 34:1997;1731.
33. All the compounds described in Table 1 gave spectroscopic data (IR, RMN, MS) and acceptable CHN analysis in agreement with the assigned structures.
34. Kerr J.S., Wexler R.S., Mousa S.A., Robinson C.S., Wexler E.J., Mohamed S., Voss M.E., Devenny J.J., Czerniak P.M.M., Gudzelak A. Jr., Slee A.M. Anticancer Res. 19:1999;959.
35. 50s obtained after fitting the dose-response sets of at least two experiments per product (with comparable results) with a sigmoid curve with variable slope. For clarity, 95% confidence intervals are not shown.
36. Mousa S.A., Bozarth J.M., Forsythe M.S., Lorelli W., Thoolen M.J., Ramachandran N., Jackson S., De Grado W., Reilly T.M. Cardiology. 83:1993;374.
37. Carreiras F., Lehmann M., Sichel F., Marvaldi J., Gauduchon P., Le Talaer J.-Y. Int. J. Cancer. 63:1995;530.
38. (a) Metabolic bioavailability predictions (MF%) were based on in vitro metabolic stability measurements with hepatic microsomes assuming total absorption. Unchanged drugs were quantified by LC-MS-MS following incubation (0.1 μM) with rat and human hepatic microsomes (0.33 mg prot/mL) after 0, 5, 15, 30 and 60 min of incubation. The in vitro intrinsic clearances (vitro CLint) were the slope (after LN linearisation) of the curve of the unchanged drug remaining concentration versus incubation time. In vitro CLint were then scaled up to in vivo whole body (vivo CLint) using 0.045 mg prot/kg of liver and liver weight of 11 g for the rat and 1.2 kg for man. In vivo CLint were then transformed into hepatic clearances (CLhep) using the equation [CLhep=vivo CLint.HBF/(vivo CLint + HBF)] where HBF (hepatic blood flow) were taken as 22 mL/min for the rat and 1500 mL/min for man. The MF% were then calculated with the following equation [MF%=100(1-CLhep/HBF)].
39. Bertrand, M.; Jackson, P.; Walther, B. Eur. J. Pharm. Sci. 2000, 11 (Suppl 2), S61.
40. Yee, S. Pharmaceut. Res. 1997, 14, 763.
41. Pierschbacher M.D., Ruoslahti E. J. Biol. Chem. 262:1987;17294.